The trademark application was filed by Cytokinetics, Incorporated, a U.S. corporation (the "Applicant"). The application was published for oppositions on February 7, 2023, and it was registered by office on May 17, 2023 without any oppositions.
The application was filed in English (French was selected as the second language).
Appointment and Replacement of representative of the trademark registration was recorded on May 25, 2023. Appointment and Replacement of representative of the trademark registration was recorded on February 11, 2024.
Goods And Services
The mark was filed in class 5 with Human pharmaceuticals for the treatment of cardiovascular diseases, pulmonary diseases, pulmonary conditions, bronchoconstrictive diseases, bronchoconstrictive conditions, diseases and conditions associated with cardiac muscle dysfunction, cardiac muscle wasting, cardiac muscle atrophy, cardiac muscle weakness, infectious diseases, neurological diseases and conditions, neuromuscular diseases and conditions, musculoskeletal disorders, and diseases and conditions associated with skeletal muscle dysfunction and human pharmaceuticals for the treatment of skeletal muscle wasting, skeletal muscle atrophy, skeletal muscle weakness, metabolic diseases and disorders, diabetes, hypertension, vascular diseases, and diseases and conditions associated with dysfunction of non-muscle myosin..
The mark was filed in class 42 with following description of goods:
Consultation and collaboration relating to drug discovery and patient diagnosis
Research in the field of cellular assay screening and pharmaceutical discovery and development